Список проголосовавших за комментарий " Capnia upgraded to Buy at Maxim Group; tgt $5 (0.82)Maxim Group upgrades CAPN to Buy from Hold and sets target price at $5. Capnia is transforming itself from a low margin high spend diagnostics company to a high margin — low spending rare-disease company with what firm views as a de-risked (safety, PK) drug in DCCR. Given the positive data thus far and clinical path laid out by Zafgen, they believe Capnia can be successful in PWS."